GAMMA Investing’s CAMP4 Therapeutics CAMP Stock Holding History

GAMMA Investing’s Portfolio CAMP Stock Details CAMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$974	Buy	+241	New	+$989	﹤0.01%	4105

Other funds holding CAMP

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

SJS Investment Consulting Sylvania, Ohio $993M AUM 16.29% 1-Year Est. Return

Caitong International Asset Management Hong Kong $1.04B AUM 150.26% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

GAMMA Investing's CAMP Position: Q3 2026 in Review

GAMMA Investing opened a new position in CAMP4 Therapeutics (CAMP) in Q3 2026: 241 shares worth $974. The stake represents ﹤0.01% of the portfolio and ranks #4105 among its holdings.

13 funds tracked by Wall St. Rank hold CAMP as of Q3 2026.

GAMMA Investing held 241 shares of CAMP4 Therapeutics worth $974 as of Q3 2026.
CAMP4 Therapeutics was a new GAMMA Investing position in Q3 2026.
CAMP4 Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #4105 holding.
13 funds tracked by Wall St. Rank held CAMP4 Therapeutics as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.